Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions.
Last updated September 11, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. It focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia, and is developing innovative treatments including AXS-05, AXS-12, and AXS-14. Its product portfolio includes AUVELITY (dextromethorphan-bupropion), Sunosi (solriamfetol), and SYMBRAVO (meloxicam and rizatriptan).
Products and positioning
AUVELITY (dextromethorphan-bupropion)
Indicated for Alzheimer's Disease Agitation (ADA).
Sunosi (solriamfetol)
Available in North America (U.S., Canada) and Europe (Great Britain, European Union).
SYMBRAVO (meloxicam and rizatriptan)
A product in the Axsome portfolio.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/axsome-therapeutics · Editorial policy · How profiles are compiled